The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 13 of the 24 sources its claims cite were checked for support.
Invasive candidiasis species distribution and trends, United States, 2009-2017
Open accessAbstract
BACKGROUND: Invasive candidiasis (IC) is a growing concern among US healthcare facilities. A large-scale study evaluating incidence and trends of IC in the United States by species and body site is needed to understand the distribution of infection. METHODS: An electronic medical record database was used to calculate incidence and trends of IC in the United States by species and infection site from 2009 through 2017. Hospital incidence was calculated using total unique inpatient hospitalizations in hospitals reporting at least 1 Candida case as the denominator. IC incidence trends were assessed using generalized estimating equations with exchangeable correlation structure to fit Poisson regression models, controlling for changes in hospital characteristics and case mix over time. RESULTS: Candida albicans remains the leading cause of IC in the United States, followed by Candida glabrata. The overall incidence of IC was 90/100 000 patients, which did not change significantly over time. There were no changes in incidence among C. albicans, C. glabrata, C. parapsilosis, or C. tropicalis; the incidence of other Candida spp. as a whole increased 7.2% annually. While there was no change in candidemia 2009-2017, abdominal and nonabdominal sterile site IC increased significantly. CONCLUSIONS: Nonbloodstream IC is increasing in the United States. Understanding the epidemiology of IC should facilitate improved management of infected patients.
Overview
CoChat Summary
TL;DR
Invasive candidiasis (IC) incidence in a large US electronic health record database was 90 per 100,000 hospitalizations from 2009–2017 and did not change significantly overall. Although candidemia remained stable, nonbloodstream IC—especially abdominal and nonabdominal sterile site infections—increased significantly.
Key findings
- Among 18,728 invasive Candida isolates from 17,103 encounters, C. albicans was most common (48%, n = 8989), followed by C. glabrata (24%, n = 4432), C. parapsilosis (11%, n = 1969), C. tropicalis (7%, n = 1295), and other Candida spp. (6%, n = 1189).
- Overall IC incidence was 90/100,000 hospitalizations, with no significant annual change (APC, 1.3%; 95% CI, −1.5% to 4.1%); incidence increased only for other Candida spp. as a group (APC, 7.2%; 95% CI, 2.8%–12%).
- Candidemia incidence did not change significantly overall, but decreased for C. albicans (APC, −3.2%; 95% CI, −6.1% to −.1%); abdominal IC increased 5.5% annually (95% CI, 1.8%–9.3%) and nonabdominal sterile site IC increased 10% annually (95% CI, 5.0%–16%).
- Unadjusted mortality was higher for C. glabrata than C. albicans (27% vs 22%, P < .001) and lower for C. parapsilosis than C. albicans (17% vs 21%, P < .001); mortality was 28% for candidemia, 16% for abdominal IC, and 10% for nonabdominal sterile site IC.
Methods
- Retrospective analysis of the Cerner HealthFacts electronic medical record database, including linked records for more than 63 million US patients; the study extracted hospital encounters from 2009–2017 with Candida isolated from blood, sterile abdominal, or other nonabdominal sterile sites.
- The analytic population included 19,381,763 unique inpatient encounters at 203 hospitals reporting at least 1 Candida case; 18,728 Candida isolates from 17,103 encounters and 16,334 patients were identified, with only the first encounter counted if the same species was isolated within 30 days.
- Hospital incidence used total unique inpatient hospitalizations in hospitals reporting at least 1 Candida case as the denominator; trends were assessed with generalized estimating equations using an exchangeable correlation structure to fit Poisson regression models, controlling for hospital characteristics and case mix over time.
Limitations
- The authors state that sterile site infections and candidemic patients with deep-seated infections may be missed because of limitations in current detection methods, and that species identification systems varied across more than 200 hospitals without centralized confirmatory testing.
- The authors state that only one-third of Candida isolates were tested for in vitro antifungal resistance, so resistance could not be assessed directly; hospitals also did not necessarily participate every year, with only 55 of 203 hospitals continuously reporting Candida throughout the study period.
- The authors state that participation was elective and that 93 hospitals reporting microbiology but no Candida cases were primarily small, nonteaching facilities largely in the West, limiting generalizability; they also note possible incomplete 2017 reporting, though trends did not change when that year was excluded.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
11 Valid · 0 Not valid · 2 Not checked · 38 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“with the sensitivity of blood culture around or less than 50% [28].”
What the sources say
- Supportedcites [28] Clancy, 2018, Diagnosing invasive candidiasis, J Clin Microbiol source
The Introduction states that, across the spectrum of invasive candidiasis, blood-culture sensitivity is approximately 50%. It also reports lower sensitivity in some forms of deep-seated infection, consistent with 'around or less than 50%.’ (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“One limitation is that we may be missing sterile site infections as well as candidemic patients with deep-seated infections due to limitations with current detection methods [28].”
What the sources say
- Supportedcites [28] Clancy, 2018, Diagnosing invasive candidiasis, J Clin Microbiol source
The Introduction, under “Cultures and diagnosing the spectrum of invasive candidiasis,” reports that blood cultures are positive in only about 40% of patients with candidemia complicated by deep-seated infection. It also says cultures from deep infection sites are only about 50% sensitive, supporting the possibility that current methods miss both types of infection. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While several studies using larger cohorts to study illness and outcomes exist [11, 15–17], species-specific data from a broadly representative population have been lacking”
What the sources say
- Partly supportedcites [11] Strollo, 2017, Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002–2012, Emerg Infect Dis sourceExperimental — accuracy not yet measured
The Abstract (page not available) says current nationally representative US data with state-specific estimates were lacking. It does not specifically say that species-specific data from a broadly representative population were lacking; the Methods describe diagnosis-code data rather than species-level data. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [15] Castanheira, 2014, Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections, Int J Antimicrob Agents source
- Not checked — no full text of the sourcecites [16] Castanheira, 2016, Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013), Diagn Microbiol Infect Dis source
- Partly supportedcites [17] Chiotos, 2016, Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12), J Antimicrob Chemother sourceExperimental — accuracy not yet measured
The Introduction of Chiotos et al. (2016) supports the 'species-specific data have been lacking' half: it records that the available C. parapsilosis-specific evidence is subgroup analyses of randomized trials that 'are underpowered to draw definitive conclusions' (Discussion) plus a single 103-episode observational cohort, and that 'a paucity of clinical data precludes a more definitive statement of equivalence'. Nothing in our copy frames the gap as one of population representativeness — the source never characterizes prior species-specific data as drawn from unrepresentative populations, so the 'broadly representative population' qualifier is not attributable to it. Indeed our copy is itself a multicentre species-specific cohort ('patient level and microbiological data from 115 US hospitals', Data source section; 307 adults with C. parapsilosis candidaemia), which the authors present as filling the paucity, so citing it for the proposition that such data are lacking overstates what it says. (LLM, conf=0.65)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients with C. glabrata infections had a significantly higher unadjusted mortality than patients with C. albicans (27% vs 22%, P < .001)”
plainstates an associationn = 4,432 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Unadjusted mortality was significantly higher in patients with candidemia (28%), compared to abdominal IC (16%, P < .001), and nonabdominal sterile site IC (10%, P < .001).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 51 claims and every source verdict.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“More recent data using US electronic medical records showed there was no significant change in the incidence between 2009–2017, with an overall incidence of inpatient IC of 90 per 100,000 hospitalizations.34”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [34]
In the citing paper
“the changing epidemiology towards nonalbicans Candida spp”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RESULTS
“One patient with C. albicans and 1 patient with C. parapsilosis had unknown sex.”
§ RESULTS
“Total 16 334 8764 4304 1892 1271 1164 Sex Female 8069 (49) 4376 (50) 2312 (54)* 823 (43)* 598 (47) 570 (49) Male 8263 (51) 4386 (50) 1992 (46)* 1069 (57)* 673 (53) 594 (51)”
Citations
Cites
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“These methodological differences hamper efforts to obtain accurate estimates of the burden of IC in the United States and globally, and may result in an underestimation of the true number of cases [5, 21].”
BackgroundPappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Self-citationKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Candida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Global trends in the distribution of Candida species causing candidemia
Guinea, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12539 · Cited by 680
Changes in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
Cited by
Pathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
Self-citationLass-Flörl, C., Kanj, S. S., Govender, N. P., Thompson, G. R., Ostrosky- Zeichner, L., & Govrins, M. A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00503-3 · Cited by 298
“The burden of disease is markedly higher in hospitalized patients worldwide (~100 per 100,000 admissions) 14–16 , with the highest incidence in patients in the ICU, reaching 5.5–7 episodes per 1,000 ICU admissions 12,17,18 .”
InfluentialIncreased incidence of candidemia in a tertiary care hospital with the COVID‐19 pandemic
Nucci, M., Barreiros, G., Guimarães, L. F., Deriquehem, V. A. S., Castiñeiras, A. C., & Nouér, S. A. (2021) · Mycoses · doi:10.1111/myc.13225 · Cited by 193
Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02324-8 · Cited by 192
Drummond, R. A., Desai, J. V., Ricotta, E. E., Swamydas, M., Deming, C., Conlan, S., Quinones, M., Matei-Rascu, V., Sheriff, L., Lecky, D., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.04.013 · Cited by 141
Self-citation
Metadata
- Authors
- Ricotta, E. E., Lai, Y. L., Babiker, A., Strich, J. R., Kadri, S. S., Lionakis, M. S., Prevots, D. R., & Adjemian, J.
- Affiliations
- National Institutes of Health (US)
- Emory University (US)
- Corresponding author
- Ricotta, Emily E
- ORCID
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-15
- Volume
- 223
- Issue
- 7
- Pages
- 1295-1302
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC8030726
- OpenAlex
- W3049534229
- Cited by
- 114
- References
- 35
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 19 · 2023: 17 · 2022: 18 · 2021: 21 · 2020: 3
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Infectious Diseases (publishedVersion, public-domain)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health Clinical Center
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- invasive candidiasis, Candida species distribution, Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, candidemia, incidence trends, hospitalization, United States
- MeSH terms
- Antifungal Agents, Candida, Humans, Microbial Sensitivity Tests, United States, Incidence, Candidiasis, Invasive, Candidemia, Introduced Species
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Invasive candidiasis species distribution and trends, United States, 2009-2017. https://app.cochat.ai/papers/10.1093/infdis/jiaa502
- The paper
- Ricotta, E. E., Lai, Y. L., Babiker, A., Strich, J. R., Kadri, S. S., Lionakis, M. S., Prevots, D. R., & Adjemian, J. (2021). Invasive candidiasis species distribution and trends, United States, 2009-2017. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaa502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.